About Centrosome-associated protein 350
Centrosome-associated protein 350 (CEP350) is a protein
from Homo sapiens identified by UniProt accession
Q5VT06, 3117 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Centrosome-associated protein 350 |
|---|
| UniProt accession | Q5VT06 |
|---|
| Gene | CEP350 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3117 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (44)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- mean reticulocyte volume · score 0.34
- mean corpuscular hemoglobin concentration · score 0.28
- lysosomal storage disease · score 0.26
- mean corpuscular volume · score 0.23
- mean corpuscular hemoglobin · score 0.23
- smoking initiation · score 0.18
- red blood cell density measurement · score 0.17
- monocyte percentage of leukocytes · score 0.06
- cyst · score 0.06
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3117 residues)
MRSSKSKEVP LPNPRNSQSK DTVQADITTS WDALSQTKAA LRHIENKLEV APTSTAVCDS VMDTKKSSTS ATRKISRKDG RYLDDSWVNA PISKSTKSRK EKSRSPLRAT TLESNVKKNN RVEFREPLVS YREIHGAPSN FSSSHLESKH VYCVDVNEEK TESGNWMIGS REERNIRSCD FESSQSSVIN DTVVRFLNDR PAIDALQNSE CLIRMGASMR TEEEMPNRTK GSENNLKLSV NNMAHDTDPK ALRLTDSSPS STSTSNSQRL DILKRRQHDV KLEKLKERIR KQWEHSEETN GRGQKLGHID HPVMVVNVDN SVTAKVRKVA TAPPAPAYKG FNPSETKIRT PDGKVWQEAE FQNMSRELYR DLALHFADDI SIKEKPAEKS KEKKVVKPVR KVQKVAQLSS TECRTGSSHL ISTSSWRDGQ KLVKKILGPA PRMEPKEQRT ASSDRGGRER TAKSGGHIGR AESDPRLDVL HRHLQRNSER SRSKSRSENN IKKLASSLPD NKQEENTALN KDFLPIEIRG ILDDLQLDST AHTAKQDTVE LQNQKSSAPV HAPRSHSPVK RKPDKITANE DPPVISKRRH YDTDEVRQYI VRQQEERKRK QNEEKKAQKE ATEQKNKRLQ ELYRKQKEAF TKVKNVPPSE PSATRRLQET YSKLLLEKTL LEEPSHQHVT QETQAKPGYQ PSGESDKENK VQERPPSASS SSDMSLSEPP QPLARKDLME STWMQPERLS PQVHHSQPQP FAGTAGSLLS HLLSLEHVGI LHKDFESILP TRKNHNMASR PLTFTPQPYV TSPAAYTDAL LKPSASQYKS KLDRIEALKA TAASLSSRIE SEAKKLAGAS INYGSAWNTE YDVQQAPQED GPWTKAVTPP VKDDNEDVFS ARIQKMLGSC VSHATFDDDL PGVGNLSEFK KLPEMIRPQS AISSFRVRSP GPKPEGLLAQ LCKRQTDSSS SDMQACSQDK AKISLGSSID SVSEGPLLSE GSLSEEEGDQ DGQPLLKVAE ILKEKEFCPG ERNSYEPIKE FQKEAEKFLP LFGHIGGTQS KGPWEELAKG SPHSVINIFT KSYQLYGKGF EDKLDRGTST SRPLNATATP LSGVSYEDDF VSSPGTGTST EKKSTLEPHS TLSPQEDHSN RKSAYDPSSV DVTSQHSSGA QSAASSRSST SSKGKKGKKE KTEWLDSFTG NVQNSLLDEE KAERGSHQGK KSGTSSKLSV KDFEQTLDTD STLEDLSGHS VSVSSDKGRS QKTPTSPLSP SSQKSLQFDV AGTSSERSKS SVMPPTITGF KPNAPLTDLN PAASRTTTEN MAPIPGSKRF SPAGLHHRMA AELSYLNAIE ESVRQLSDVE RVRGISLAQQ ESVSLAQIIK AQQQRHERDL ALLKLKAEQE ALESQRQLEE TRNKAAQVHA ESLQQVVQSQ REVTEVLQEA TCKIAAQQSE TARLTTDAAR QICEMAELTR THISDAVVAS GAPLAILYDH QRQHLPDFVK QLRTRTETDR KSPSVSLSQS KEGTLDSKHQ KYSASYDSYS ESSGYKNHDR RSSSGSSRQE SPSVPSCKEN EKKLNGEKIE SSIDEQVQTA ADDSLRSDSV PSLPDEKDST SIATEYSLKF DESMTEDEIE EQSFRSLLPS ESHRRFNMEK RRGHHDDSDE EASPEKTTLS TAKELNMPFS GGQDSFSKFT MEMVRQYMKE EEMRAAHQSS LLRLREKALK EKTKAELAWL EHQKKHLRDK GEDDKMPPLR KKQRGLLLRL QQEKAEIKRL QEANKAARKE RQLILKQQEE IEKIRQTTIK LQEKLKSAGE SKLDSHSDDD TKDNKATSPG PTDLETRSPS PISISSSETS SIMQKLKKMR SRMDEKFLTK REQKLMQRRQ HAEELLEWKR RLDAEEAEIR QMEKQALAAW DKELIKPKTP KKELEDQRTE QKEIASEEES PVPLYSHLNS ESSIPEELGS PAVEYVPSES IGQEQPGSPD HSILTEEMIC SQELESSTSP SKHSLPKSCT SVSKQESSKG SHRTGGQCHL PIKSHQHCYS WSDESLSMTQ SETTSDQSDI EGRIRALKDE LRKRKSVVNQ LKKEQKKRQK ERLKAQEASL IKQLESYDEF IKKTEAELSQ DLETSPTAKP QIKTLSSASE KPKIKPLTPL HRSETAKNWK SLTESERSRG SLESIAEHVD ASLSGSERSV SERSLSAYAK RVNEWDSRTE DFQTPSPVLR SSRKIREESG DSLENVPALH LLKELNATSR ILDMSDGKVG ESSKKSEIKE IEYTKLKKSK IEDAFSKEGK SDVLLKLVLE QGDSSEILSK KDLPLDSENV QKDLVGLAIE NLHKSEEMLK ERQSDQDMNH SPNIQSGKDI HEQKNTKEKD LSWSEHLFAP KEIPYSEDFE VSSFKKEISA ELYKDDFEVS SLLSLRKDSQ SCRDKPQPMR SSTSGATSFG SNEEISECLS EKSLSIHSNV HSDRLLELKS PTELMKSKER SDVEHEQQVT ESPSLASVPT ADELFDFHIG DRVLIGNVQP GILRFKGETS FAKGFWAGVE LDKPEGNNNG TYDGIAYFEC KEKHGIFAPP QKISHIPENF DDYVDINEDE DCYSDERYQC YNQEQNDTEG PKDREKDVSE YFYEKSLPSV NDIEASVNRS RSLKIETDNV QDISGVLEAH VHQQSSVDSQ ISSKENKDLI SDATEKVSIA AEDDTLDNTF SEELEKQQQF TEEEDNLYAE ASEKLCTPLL DLLTREKNQL EAQLKSSLNE EKKSKQQLEK ISLLTDSLLK VFVKDTVNQL QQIKKTRDEK IQLSNQELLG DDQKKVTPQD LSQNVEEQSP SISGCFLSSE LEDEKEEISS PDMCPRPESP VFGASGQEEL AKRLAELELS REFLSALGDD QDWFDEDFGL SSSHKIQKNK AEETIVPLMA EPKRVTQQPC ETLLAVPHTA EEVEILVHNA AEELWKWKEL GHDLHSISIP TKLLGCASKG LDIESTSKRV YKQAVFDLTK EIFEEIFAED PNLNQPVWMK PCRINSSYFR RVKNPNNLDE IKSFIASEVL KLFSLKKEPN HKTDWQKMMK FGRKKRDRVD HILVQELHEE EAQWVNYDED ELCVKMQLAD GIFETLIKDT IDVLNQISEK QGRMLLV
Explore Centrosome-associated protein 350 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets